Kirk Christopher J. 4
4 · Kezar Life Sciences, Inc. · Filed Feb 5, 2020
Insider Transaction Report
Form 4
Kirk Christopher J.
DirectorCEO
Transactions
- Purchase
Common Stock
2020-02-04$2.60/sh+38,461$99,999→ 342,609 total
Footnotes (2)
- [F1]Shares were purchased in a public offering of the Issuer at a public offering price of $2.60.
- [F2]Total reflects 1,214 shares of common stock acquired on November 15, 2019 through the Company's 2018 Employee Stock Purchase Plan.